The use of macrolide antibiotics in patients with cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 6, 2004, Pages 515-523

  Saiman, Lisa ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Azithromycin; Cystic fibrosis; Macrolides; Pulmonary function

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CHEMOKINE; CLARITHROMYCIN; CYTOKINE; DEOXYRIBONUCLEASE; ERYTHROMYCIN; GAMMA GLUTAMYLTRANSFERASE; GLYCOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MACROLIDE; MUCIN; NUCLEAR FACTOR; QUINOLONE; ROXITHROMYCIN; TOBRAMYCIN; TRANSCRIPTION FACTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BRONCHOSPASM; BRONCHUS REACTIVITY; BURKHOLDERIA CEPACIA; CLINICAL TRIAL; CROSS RESISTANCE; CYSTIC FIBROSIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLOW KINETICS; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; LIVER TOXICITY; LUNG FUNCTION; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NAUSEA; NONHUMAN; OTOTOXICITY; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; RASH; REVIEW; SPUTUM; SYSTEMATIC REVIEW; TINNITUS; VOMITING; WEIGHT GAIN; WHEEZING;

EID: 7444244914     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000142101.53084.f0     Document Type: Review

References (72)

1. Hoiby N: Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994, 49:531-532.
2. Sugiyama Y: Diffuse panbronchiolitis. Clin Chest Med 1993, 14:765-772.
3. Kudoh S, Azuma A, Yamamoto M, et al.: Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
4. Anstead MI, Kuhn RJ, Hartford LH, et al.: Effect of chronic azithromycin on lung function in cystic fibrosis [abstract no. 421]. Pediatr Pulmonol 1999, 28:283-284.
5. Jaffe A, Francis J, Rosenthal M, et al.: Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998, 351:420.
6. Pirzada OM, Taylor CJ: Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract no. 348]. Pediatr Pulmonol 1999, 28:263.
7. App EM, Konig K, Duffner U, et al.: The effects of azithromycin therapy on sputum inflammation in CF lung disease [abstract]. Am J Respir Crit Care Med 2000, 161:758.
8. Frederiksen B, Koch C, Hoiby N, et al.: Clinical efficacy of clarithromycin in CF patients with chronic lung infection. In Abstracts of the 24th European Cystic Fibrosis Conference. Vienna: 2001:P208 [abstract].
9. Wolter J, Seeney S, Bell S, et al.: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216. This randomized trial demonstrates the clinical benefit of azithromycin in adult patients with CF.
10. Equi A, Balfour-Lynn IM, Bush A, et al.: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984. This randomized trial demonstrates the clinical benefit of azithromycin in children with CF with and without chronic infection with P. aeruginosa.
11. Saiman L, Marshall BC, Mayer-Hamblett N, et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756. This randomized trial demonstrates the clinical benefit of azithromycin in children and adults with CF with chronic infection with P. aeruginosa. A large number of secondary end points were shown to be improved and were found to be well tolerated. Only nausea, diarrhea, and wheezing increased in azithromycin participants compared with placebo participants.
12. Southern K, Barker P, Sous A: Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004, 2:CD002203. This is a meta-analysis of the three randomized clinical trials in CF confirming the benefit of azithromycin. Future areas of research are delineated.
13. Ramsey BW: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335:179-188.
14. Riordan JR, Rommens JM, Kerem B, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
15. Boucher RC: Molecular insights into the physiology of the 'thin film' of airway surface liquid. J Physiol 1999, 516:631-638.
16. Gilligan PH: Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991, 4:35-51.
17. Givney R, Vickery A, Holliday A, et al.: Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect 1997, 35:27-36.
18. Saiman L, Mehar F, Niu WW, et al.: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996, 23:532-537.
19. Taccetti G, Campana S, Marianelli L: Multiresistant non-fermentative Gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Eur J Epidemiol 1999, 15:85-88.
20. Burns JL, Van Dalfsen JM, Shawar RM, et al.: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999, 179:1190-1196.
21. Olivier KN, Weber DJ, Lee JH, et al.: Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003, 167:835-840.
22. Olivier KN, Weber DJ, Wallace RJ, et al.: Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834. This is a large, multicenter prevalence study of nontuberculous mycobacteria showing increased prevalence with age and that Mycobacterium avium complex is the most common species isolated.
23. Costerton JW: Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 2001, 9:50-52.
24. Singh PK, Schaefer AL, Parsek MR, et al.: Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407:762-764.
25. Costerton JW, Stewart PS: Battling biofilms. Sci Am 2001, 285:74-81.
26. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
27. Olsen KM, San Pedro G, Gann LP, et al.: Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996, 40:2582-2585.
28. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990, 25(suppl A): 73-82.
29. Rosen JM, Smith TC, Myerholtz KA, et al.: Azithromycin Levels in Sputum of Patients With Cystic Fibrosis. Barcelona: ICMAS; 1998.
30. Cipolli M, Cazzola G, Novelli A, et al.: Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest 2001, 21:353-360.
31. Physicians' Desk Reference, edn 58. Montvale, NJ: Thomson PDR; 2004:2675-2690.
32. Saiman L: What have we learned from further analysis of the U.S. macrolide trial?: Subgroup analyses of azithromycin trial. Pediatr Pulmonol 2003, 36:165-167.
33. Ramsey BW, Pepe MS, Quan JM, et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30.
34. Turner MA, Baildam E, Patel L, et al.: Joint disorders in cystic fibrosis. J R Soc Med 1997, 90:13-20.
35. Eady EA, Ross JI, Tipper JL, et al.: Distribution of genes encoding erythromycin ribosomal methylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. J Antimicrob Chemother 1993, 31:211-217.
36. Prunier AL, Malbruny B, Laurans M, et al.: High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003, 187:1709-1716. This prevalence study of macrolide-resistant S. aureus in CF serves as a warning for the emergence of resistance.
37. Doucet-Populaire F, Buriankova K, Weiser J, et al.: Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2002, 2:355-370.
38. Tamaoki J: The effects of macrolides on inflammatory cells. Chest 2004, 125:413-503.
39. Gotfried MH: Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004, 125:52S-61S. This is an excellent review of the subject detailing potential clinical utility and mechanism of action.
40. Wozniak DJ, Keyser R: Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004, 125:623-693.
41. Rubin BK, Henke MO: Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004, 125:703-783. This is a thorough review of the potential antiinflammatory mechanism of action of macrolide antibiotics.
42. Labro MT: Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998, 41:37-46.
43. Scaglione F, Rossoni G: Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998, 41 (suppl B):47-50.
44. Ianaro A, Ialenti A, Maffia P, et al.: Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292:156-163.
45. Levert H, Gressier B, Moutard I, et al.: Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation 1998, 22:191-201.
46. Ichikawa Y, Ninomiya H, Koga H, et al.: Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992, 146:196-203.
47. Sakito O, Kadota J, Kohno S, et al.: Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration (Herrlisheim) 1996, 63:42-48.
48. Yanagihara K, Tomono K, Sawai T, et al.: Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997, 155:337-342.
49. Fujii T, Kadota J, Morikawa T, et al.: Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob Agents Chemother 1996, 40:1548-1551.
50. Kawasaki S, Takizawa H, Ohtoshi T, et al.: Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998, 42:1499-1502.
51. Tateda K, Ishii Y, Matsumoto T, et al.: Direct evidence for antipseudomonal activity of macrolides: Exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996, 40:2271-2275.
52. Dupont MJ, Lapointe JR: Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. J Antimicrob Chemother 1995, 36:231-236.
53. Mattick JS: Type IV pili and twitching motility. Annu Rev Microbiol 2002, 56:289-314. This is an excellent review of the pathogenesis of adherence and biofilms.
54. Mizukane R, Hirakata Y, Kaku M, et al.: Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994, 38:528-533.
55. Molinari G, Guzman CA, Pesce A, et al.: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993, 31:681-688.
56. Tateda K, Ishii Y, Hirakata Y, et al.: Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity. J Antimicrob Chemother 1994, 34:931-942.
57. Tateda K, Hirakata Y, Furuya N, et al.: Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993, 37:675-680.
58. Tsang KW, Ng P, Ho PL, et al.: Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J 2003, 21:401-406.
59. Tsang KW, Shum DK, Chan S, et al.: Pseudomonas aeruginosa adherence to human basement membrane collagen in vitro. Eur Respir J 2003, 21:932-938.
60. Saiman L, Chen Y, Gabriel PS, et al.: Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002, 46:1105-1107.
61. Tateda K, Comte R, Pechere JC, et al.: Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001, 45:1930-1933.
62. Favre-Bonté S, Köhler T, Van Delden C: Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J Antimicrob Chemother 2003, 52:598-604.
63. Itkin IH, Menzel ML: The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970, 45:146-162.
64. Szefler SJ, Rose JQ, Ellis EF, et al.: The effect of troleandomycin on methyl-prednisolone elimination. J Allergy Clin Immunol 1980, 66:447-451.
65. Black PN, Blasi F, Jenkins CR, et al.: Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001, 164:536-541.
66. Kraft M, Cassell GH, Pak J, et al.: Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002, 121:1782-1788.
67. Tamaoki J, Takeyama K, Yamawaki I, et al.: Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997, 272:L15-L19.
68. Tamaoki J, Nakata J, Tagaya E, et al.: Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas. Antimicrob Agents Chemother 1996, 40:1726-1728.
69. Tamaoki J, Takeyama K, Tagaya E, et al.: Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995, 39:1688-1690.
70. Tagaya E, Tamaoki J, Kondo M, et al.: Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002, 122:213-218.
71. Emre U, Bernius M, Roblin PM, et al.: Chlamydia pneumoniae infection in patients with cystic fibrosis. Clin Infect Dis 1996, 22:819-823.
72. Ramsey BW, Astley SJ, Aitken ML, et al.: Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993, 148:145-151.